CRISPR Therapeutics Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
480
- Stock Symbol
-
CRSP
- Investments
-
8
- Share Price
-
$38.93
- (As of Thursday Closing)
CRISPR Therapeutics General Information
Description
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Contact Information
Website
www.crisprtx.comCorporate Office
- Baarerstrasse 14
- V8
- 6300 Zug
- Switzerland
Corporate Office
- Baarerstrasse 14
- V8
- 6300 Zug
- Switzerland
CRISPR Therapeutics Timeline
CRISPR Therapeutics Stock Performance
As of 19-Nov-2026, CRISPR Therapeutics’s stock price is $38.93. Its current market cap is $3.78B with 97M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $38.93 | $40.19 | $38.37 - $63.45 | $3.78B | 97M | 1.73M | -$4.75 |
CRISPR Therapeutics Financials Summary
As of 30-Sep-2026, CRISPR Therapeutics has a trailing 12-month revenue of $23.3M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,768,434 | 3,292,858 | 1,651,413 | 3,474,231 |
| Revenue | 23,323 | 0 | 35,000 | 370,000 |
| EBITDA | (435,150) | (558,486) | (343,406) | (130,885) |
| Net Income | (456,135) | (581,599) | (366,252) | (153,610) |
| Total Assets | 2,556,412 | 2,265,243 | 2,242,034 | 2,229,571 |
| Total Debt | 779,827 | 206,746 | 223,693 | 238,632 |
CRISPR Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CRISPR Therapeutics Comparisons
Industry
Financing
Details
CRISPR Therapeutics Competitors (36)
One of CRISPR Therapeutics’s 36 competitors is Editas Medicine, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Editas Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Beam Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA |
CRISPR Therapeutics Patents
CRISPR Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026210442-A1 | Methods and compositions for cellular selection and in vivo tissue enrichment | Pending | 03-Apr-2025 | ||
| WO-2026190732-A1 | Chemically modified poly(a) tail sequences | Pending | 12-Mar-2025 | ||
| WO-2026180998-A1 | Pam diversification of cas9 variants | Pending | 26-Feb-2025 | ||
| WO-2026180997-A1 | Synthetic nucleotide template polymerase (syntase) editing | Pending | 26-Feb-2025 | ||
| WO-2026078565-A1 | Messenger rna encoding cas9 for use in genome-editing systems | Pending | 10-Oct-2024 | C12N15/85 |
CRISPR Therapeutics Signals
CRISPR Therapeutics Investments & Acquisitions (8)
CRISPR Therapeutics’s most recent deal was a Later Stage VC with Seawolf Therapeutics for . The deal was made on 16-Nov-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Seawolf Therapeutics | 16-Nov-2026 | Later Stage VC | Drug Discovery | ||
| Averna Therapeutics | 19-Mar-2026 | Early Stage VC | Pharmaceuticals | ||
| Sirius Therapeutics | 22-Sep-2025 | Early Stage VC | Drug Discovery | ||
| ERS Genomics | 01-Jan-2022 | Merger/Acquisition | Biotechnology | ||
| Casebia Therapeutics | 13-Dec-2019 | Merger/Acquisition | Drug Discovery |
CRISPR Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
34.66 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
CRISPR Therapeutics Exits (2)
CRISPR Therapeutics’s most recent exit was on 25-Sep-2018 from ViaCyte. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| ViaCyte | 25-Sep-2018 | Completed |
|
||
| StrideBio | 13-Jun-2018 | Early Stage VC | Completed |
|
CRISPR Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| ERS Genomics | Dublin, Ireland | 2014 |
CRISPR Therapeutics FAQs
-
When was CRISPR Therapeutics founded?
CRISPR Therapeutics was founded in 2013.
-
Where is CRISPR Therapeutics headquartered?
CRISPR Therapeutics is headquartered in Zug, Switzerland.
-
What is the size of CRISPR Therapeutics?
CRISPR Therapeutics has 480 total employees.
-
What industry is CRISPR Therapeutics in?
CRISPR Therapeutics’s primary industry is Drug Discovery.
-
Is CRISPR Therapeutics a private or public company?
CRISPR Therapeutics is a Public company.
-
What is CRISPR Therapeutics’s stock symbol?
The ticker symbol for CRISPR Therapeutics is CRSP.
-
What is the current stock price of CRISPR Therapeutics?
As of 19-Nov-2026 the stock price of CRISPR Therapeutics is $38.93.
-
What is the current market cap of CRISPR Therapeutics?
The current market capitalization of CRISPR Therapeutics is $3.78B.
-
What is CRISPR Therapeutics’s current revenue?
The trailing twelve month revenue for CRISPR Therapeutics is $23.3M.
-
Who are CRISPR Therapeutics’s competitors?
Editas Medicine, Beam Therapeutics, Intellia Therapeutics, Genetix Biotherapeutics, and Caribou Biosciences are some of the 36 competitors of CRISPR Therapeutics.
-
What is CRISPR Therapeutics’s annual earnings per share (EPS)?
CRISPR Therapeutics’s EPS for 12 months was -$4.75.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process